{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T15:34:34Z","timestamp":1775921674783,"version":"3.50.1"},"reference-count":98,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T00:00:00Z","timestamp":1718755200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.xcrm.2024.101655","type":"journal-article","created":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T15:16:04Z","timestamp":1721142964000},"page":"101655","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Development of a hydrogen peroxide-inactivated vaccine that protects against viscerotropic yellow fever in a non-human primate model"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7545-4013","authenticated-orcid":false,"given":"Ian J.","family":"Amanna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Archana","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flora","family":"Engelmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erika","family":"Hammarlund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans-Peter","family":"Rau\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam L.","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth A.","family":"Poore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin K.","family":"Quintel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne D.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael K.","family":"Axthelm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda L.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lois M.A.","family":"Colgin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael S.","family":"Diamond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilhem","family":"Messaoudi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark K.","family":"Slifka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2024.101655_bib1","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1708-8305.2006.00011.x","article-title":"The US-Certified Yellow Fever Vaccination Center Registry: a tool for travelers, state health departments,\u00a0and vaccine providers","volume":"13","author":"Russell","year":"2006","journal-title":"J.\u00a0Travel Med."},{"key":"10.1016\/j.xcrm.2024.101655_bib2","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jcv.2014.08.030","article-title":"Yellow fever","volume":"64","author":"Monath","year":"2015","journal-title":"J.\u00a0Clin. Virol."},{"key":"10.1016\/j.xcrm.2024.101655_bib3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0010741","article-title":"Occurrence of yellow fever outbreaks in a partially vaccinated population: An analysis of the effective reproduction number","volume":"16","author":"Ferreira","year":"2022","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.xcrm.2024.101655_bib4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001638","article-title":"Yellow Fever in Africa: estimating the burden of disease and impact of mass vaccination from outbreak and serological data","volume":"11","author":"Garske","year":"2014","journal-title":"PLoS Med."},{"key":"10.1016\/j.xcrm.2024.101655_bib5","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.64670","article-title":"The global burden of yellow fever","volume":"10","author":"Gaythorpe","year":"2021","journal-title":"Elife"},{"key":"10.1016\/j.xcrm.2024.101655_bib6","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41541-022-00552-3","article-title":"Yellow fever resurgence: An avoidable crisis?","volume":"7","author":"Lindsey","year":"2022","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.xcrm.2024.101655_bib7","article-title":"Yellow fever stalks Brazil in Zika's wake","volume":"356","author":"Dyer","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.xcrm.2024.101655_bib8","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S1473-3099(16)30513-8","article-title":"Spread of yellow fever virus outbreak in Angola and the Democratic Republic of the Congo 2015-16: a modelling study","volume":"17","author":"Kraemer","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.xcrm.2024.101655_bib9","doi-asserted-by":"crossref","first-page":"5951","DOI":"10.1016\/j.vaccine.2017.03.032","article-title":"Yellow fever live attenuated vaccine: A very successful live attenuated vaccine but still we have problems controlling the disease","volume":"35","author":"Barrett","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.xcrm.2024.101655_bib10","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMp1606997","article-title":"Yellow Fever in Angola and Beyond--The Problem of Vaccine Supply and Demand","volume":"375","author":"Barrett","year":"2016","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2024.101655_bib11","doi-asserted-by":"crossref","first-page":"6077","DOI":"10.1016\/j.vaccine.2008.09.009","article-title":"Adverse event reports following yellow fever vaccination","volume":"26","author":"Lindsey","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.xcrm.2024.101655_bib12","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1586\/erv.12.6","article-title":"Review of the risks and benefits of yellow fever vaccination including some new analyses","volume":"11","author":"Monath","year":"2012","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.xcrm.2024.101655_bib13","doi-asserted-by":"crossref","first-page":"6201","DOI":"10.1016\/j.vaccine.2013.10.050","article-title":"How many published cases of serious adverse events after yellow fever vaccination meet Brighton Collaboration diagnostic criteria?","volume":"31","author":"Thomas","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.xcrm.2024.101655_bib14","article-title":"Enhanced safety surveillance of STAMARIL\u00ae yellow fever vaccine provided under the expanded access investigational new drug program in the USA","volume":"30","author":"Rojas","year":"2023","journal-title":"J.\u00a0Travel Med."},{"key":"10.1016\/j.xcrm.2024.101655_bib15","article-title":"Yellow fever vaccine-associated neurologic and viscerotropic disease: a 10-year case series of the French National Reference Center for arboviruses with clinical and immunological insights","volume":"31","author":"Le Hir","year":"2024","journal-title":"J.\u00a0Travel Med."},{"key":"10.1016\/j.xcrm.2024.101655_bib16","first-page":"647","article-title":"Yellow Fever Vaccine Booster Doses: Recommendations of the Advisory Committee on Immunization Practices, 2015","volume":"64","author":"Staples","year":"2015","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.xcrm.2024.101655_bib17","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1080\/14760584.2016.1198259","article-title":"Questions regarding the safety and\u00a0duration of immunity following live yellow fever vaccination","volume":"15","author":"Amanna","year":"2016","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.xcrm.2024.101655_bib18","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/s41541-020-0205-6","article-title":"Review of data and knowledge gaps regarding yellow fever vaccine-induced immunity and duration of protection","volume":"5","author":"Staples","year":"2020","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.xcrm.2024.101655_bib19","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/S1473-3099(19)30323-8","article-title":"Long-term immunity against yellow fever in children vaccinated during infancy: a longitudinal cohort study","volume":"19","author":"Domingo","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.xcrm.2024.101655_bib20","doi-asserted-by":"crossref","first-page":"7147","DOI":"10.1016\/j.vaccine.2019.09.051","article-title":"Duration of post-vaccination humoral immunity against yellow fever in children","volume":"37","author":"de Noronha","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.xcrm.2024.101655_bib21","doi-asserted-by":"crossref","first-page":"4214","DOI":"10.1016\/j.vaccine.2018.12.020","article-title":"Advanced oxidation technology for the development of a next-generation inactivated West Nile virus vaccine","volume":"37","author":"Quintel","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.xcrm.2024.101655_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1010695","article-title":"Development of a next-generation chikungunya virus vaccine based on the HydroVax platform","volume":"18","author":"Slifka","year":"2022","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.xcrm.2024.101655_bib23","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1001\/jama.1928.02690310005002","article-title":"The transmission of yellow fever to macacus rhesus: preliminary note","volume":"90","author":"Stokes","year":"1928","journal-title":"Journal of the American Medical Association"},{"key":"10.1016\/j.xcrm.2024.101655_bib24","first-page":"413","article-title":"Persistence of yellow fever immunity","volume":"5","author":"Sawyer","year":"1931","journal-title":"J Prev Med"},{"key":"10.1016\/j.xcrm.2024.101655_bib25","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1128\/am.25.4.539-544.1973","article-title":"Yellow fever vaccine: direct challenge of monkeys given graded doses of 17D vaccine","volume":"25","author":"Mason","year":"1973","journal-title":"Appl. Microbiol."},{"key":"10.1016\/j.xcrm.2024.101655_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003295","article-title":"Pathophysiologic and transcriptomic analyses of viscerotropic yellow fever in a rhesus macaque model","volume":"8","author":"Engelmann","year":"2014","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.xcrm.2024.101655_bib27","doi-asserted-by":"crossref","first-page":"32648","DOI":"10.1073\/pnas.2014096117","article-title":"Consumptive coagulopathy of severe yellow fever occurs independently of hepatocellular tropism and massive hepatic injury","volume":"117","author":"Bailey","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2024.101655_bib28","doi-asserted-by":"crossref","first-page":"431","DOI":"10.4269\/ajtmh.1981.30.431","article-title":"Pathophysiologic correlations in a rhesus monkey model of yellow fever with special observations on the acute necrosis of B cell areas of lymphoid tissues","volume":"30","author":"Monath","year":"1981","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.xcrm.2024.101655_bib29","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.ade5795","article-title":"Therapeutic neutralizing monoclonal antibody administration protects against lethal yellow fever virus infection","volume":"15","author":"Ricciardi","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xcrm.2024.101655_bib30","doi-asserted-by":"crossref","first-page":"361","DOI":"10.4049\/jimmunol.26.5.361","article-title":"On the Use of Immune Serum at Various Intervals after the Inoculation of Yellow Fever Virus into Rhesus Monkeys","volume":"26","author":"Davis","year":"1934","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.xcrm.2024.101655_bib31","doi-asserted-by":"crossref","first-page":"451","DOI":"10.4269\/ajtmh.1931.s1-11.451","article-title":"The Duration of Passive Immunity in Yellow Fever","volume":"s1\u201311","author":"Bauer","year":"1931","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.xcrm.2024.101655_bib32","doi-asserted-by":"crossref","first-page":"533","DOI":"10.4269\/ajtmh.2002.66.533","article-title":"Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial","volume":"66","author":"Monath","year":"2002","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.xcrm.2024.101655_bib33","doi-asserted-by":"crossref","first-page":"316","DOI":"10.4161\/hv.4.4.5751","article-title":"Protective immunity following vaccination: how is it defined?","volume":"4","author":"Amanna","year":"2008","journal-title":"Hum. Vaccin."},{"key":"10.1016\/j.xcrm.2024.101655_bib34","series-title":"Plotkin\u2019s Vaccines","first-page":"1251","article-title":"Yellow fever vaccine","author":"Staples","year":"2023"},{"key":"10.1016\/j.xcrm.2024.101655_bib35","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/0264-410X(94)90259-3","article-title":"Toxin inactivation and antigen stabilization: two different uses of formaldehyde","volume":"12","author":"Rappuoli","year":"1994","journal-title":"Vaccine"},{"key":"10.1016\/j.xcrm.2024.101655_bib36","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1084\/jem.20052442","article-title":"Enhancing immunogenicity by limiting susceptibility to lysosomal proteolysis","volume":"203","author":"Delamarre","year":"2006","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.xcrm.2024.101655_bib37","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1093\/infdis\/142.5.716","article-title":"Immunogenic correlation between cross-reacting material (CRM197) produced by a mutant of Corynebacterium diphtheriae and diphtheria toxoid","volume":"142","author":"Porro","year":"1980","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.xcrm.2024.101655_bib38","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1016\/j.vaccine.2010.03.023","article-title":"Inactivated yellow fever 17D vaccine: development and nonclinical safety, immunogenicity and protective activity","volume":"28","author":"Monath","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.xcrm.2024.101655_bib40","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1016\/j.vaccine.2015.03.077","article-title":"An inactivated yellow fever 17DD vaccine cultivated in Vero cell cultures","volume":"33","author":"Pereira","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.xcrm.2024.101655_bib41","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1056\/NEJMoa1009303","article-title":"An inactivated cell-culture vaccine against yellow fever","volume":"364","author":"Monath","year":"2011","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2024.101655_bib42","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1006\/biol.1995.0034","article-title":"Inactivation of DNA by beta-propiolactone","volume":"23","author":"Perrin","year":"1995","journal-title":"Biologicals"},{"key":"10.1016\/j.xcrm.2024.101655_bib39","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.00512-22","article-title":"Isolation of a Potently Neutralizing and Protective Human Monoclonal Antibody Targeting Yellow Fever Virus","volume":"13","author":"Doyle","year":"2022","journal-title":"mBio"},{"key":"10.1016\/j.xcrm.2024.101655_bib43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0041707","article-title":"A flow cytometry-based assay for quantifying non-plaque forming strains of yellow Fever virus","volume":"7","author":"Hammarlund","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.xcrm.2024.101655_bib44","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/j.vaccine.2022.11.051","article-title":"Evaluation of safety and immuno-efficacy\u00a0of a next generation live-attenuated yellow fever vaccine in\u00a0cynomolgus\u00a0macaques","volume":"41","author":"Piras-Douce","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.xcrm.2024.101655_bib45","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1001\/jama.1966.03110190153047","article-title":"Fatal viral encephalitis following 17D yellow fever vaccine inoculation. Report of a case in a 3-year-old child","volume":"198","author":"Sencer","year":"1966","journal-title":"JAMA"},{"key":"10.1016\/j.xcrm.2024.101655_bib46","first-page":"131","article-title":"Fatal myeloencephalitis following yellow fever vaccination in a case with HIV infection","volume":"85","author":"Kengsakul","year":"2002","journal-title":"J.\u00a0Med. Assoc. Thai."},{"key":"10.1016\/j.xcrm.2024.101655_bib47","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.4269\/ajtmh.2009.09-0295","article-title":"Short report: Incidence of yellow fever vaccine-associated neurotropic disease","volume":"81","author":"Guimard","year":"2009","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.xcrm.2024.101655_bib48","doi-asserted-by":"crossref","first-page":"3124","DOI":"10.1016\/j.vaccine.2007.01.078","article-title":"Neurological adverse events temporally associated to mass vaccination against yellow fever in Juiz de Fora, Brazil, 1999-2005","volume":"25","author":"Fernandes","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.xcrm.2024.101655_bib49","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.vaccine.2021.12.047","article-title":"Yellow fever vaccine usage in the United States and risk of neurotropic and viscerotropic disease: A retrospective cohort study using three healthcare databases","volume":"40","author":"Ledlie","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.xcrm.2024.101655_bib50","doi-asserted-by":"crossref","first-page":"e711","DOI":"10.1016\/S2666-5247(23)00170-2","article-title":"Transmission of yellow fever vaccine virus through blood transfusion and organ transplantation in the USA in 2021: report of an investigation","volume":"4","author":"Gould","year":"2023","journal-title":"Lancet. Microbe"},{"key":"10.1016\/j.xcrm.2024.101655_bib51","doi-asserted-by":"crossref","first-page":"E243","DOI":"10.1503\/cmaj.100619","article-title":"Case report: probable transmission of vaccine strain of yellow fever virus to an infant via breast milk","volume":"183","author":"Kuhn","year":"2011","journal-title":"CMAJ (Can. Med. Assoc. J.)"},{"key":"10.1016\/j.xcrm.2024.101655_bib52","first-page":"269","article-title":"Infant meningoencephalitis caused by yellow fever vaccine virus transmitted via breastmilk","volume":"87","author":"Traiber","year":"2011","journal-title":"J.\u00a0Pediatr."},{"key":"10.1016\/j.xcrm.2024.101655_bib53","first-page":"130","article-title":"Transmission of yellow Fever vaccine virus through breast-feeding --- Brazil, 2009","volume":"59","year":"2010","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.xcrm.2024.101655_bib54","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.tmaid.2015.10.001","article-title":"The elderly, the young and the pregnant traveler -- A retrospective data analysis from a large Swiss Travel Center with a special focus on malaria prophylaxis and yellow fever vaccination","volume":"13","author":"Jaeger","year":"2015","journal-title":"Travel Med. Infect. Dis."},{"key":"10.1016\/j.xcrm.2024.101655_bib55","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S0140-6736(01)05327-2","article-title":"Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases","volume":"358","author":"Martin","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2024.101655_bib56","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1016\/j.vaccine.2005.01.089","article-title":"Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events","volume":"23","author":"Khromava","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.xcrm.2024.101655_bib57","first-page":"244","article-title":"Age-related risk of adverse events following yellow fever vaccination in Australia","volume":"28","author":"Lawrence","year":"2004","journal-title":"Commun Dis Intell"},{"key":"10.1016\/j.xcrm.2024.101655_bib58","doi-asserted-by":"crossref","first-page":"207","DOI":"10.4161\/hv.1.5.2221","article-title":"Yellow fever 17D vaccine safety and immunogenicity in the elderly","volume":"1","author":"Monath","year":"2005","journal-title":"Hum. Vaccin."},{"key":"10.1016\/j.xcrm.2024.101655_bib59","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1016\/j.vaccine.2006.12.015","article-title":"17D yellow fever vaccines: new insights. A report of a workshop held during the World Congress on medicine and health in the tropics, Marseille, France, Monday 12 September 2005","volume":"25","author":"Barrett","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.xcrm.2024.101655_bib60","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.antiviral.2009.08.008","article-title":"Wanted, dead or alive: new viral vaccines","volume":"84","author":"Amanna","year":"2009","journal-title":"Antiviral Res."},{"key":"10.1016\/j.xcrm.2024.101655_bib61","doi-asserted-by":"crossref","first-page":"221","DOI":"10.4049\/jimmunol.30.3.221","article-title":"A study of inactivated yellow fever virus as an immunizing agent","volume":"30","author":"Gordon","year":"1936","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.xcrm.2024.101655_bib62","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2021.1895644","article-title":"Re-thinking yellow fever vaccines: fighting old foes with new generation vaccines","volume":"18","author":"Montalvo Zurbia-Flores","year":"2022","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.xcrm.2024.101655_bib63","doi-asserted-by":"crossref","DOI":"10.3390\/ph14090891","article-title":"The Present and Future of Yellow Fever Vaccines","volume":"14","author":"Hansen","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.xcrm.2024.101655_bib64","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1590\/0074-02760150176","article-title":"A randomised double-blind clinical trial of two yellow fever vaccines prepared with substrains 17DD and 17D-213\/77 in children nine-23\u00a0months old","volume":"110","year":"2015","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"10.1016\/j.xcrm.2024.101655_bib65","doi-asserted-by":"crossref","first-page":"6327","DOI":"10.1016\/j.vaccine.2011.05.019","article-title":"Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella","volume":"29","author":"Nascimento Silva","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.xcrm.2024.101655_bib66","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.3389\/fimmu.2019.02192","article-title":"Short-Lived Immunity After 17DD Yellow Fever Single Dose Indicates That Booster Vaccination May Be Required to Guarantee Protective Immunity in Children","volume":"10","author":"Campi-Azevedo","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2024.101655_bib67","first-page":"895","article-title":"Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine","volume":"59","author":"Poland","year":"1981","journal-title":"Bull. World Health Organ."},{"key":"10.1016\/j.xcrm.2024.101655_bib68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2012.02.001","article-title":"A humanized IgG but not IgM antibody is effective in prophylaxis and therapy of yellow fever infection in an AG129\/17D-204 peripheral challenge mouse model","volume":"94","author":"Thibodeaux","year":"2012","journal-title":"Antiviral Res."},{"key":"10.1016\/j.xcrm.2024.101655_bib69","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1099\/0022-1317-67-2-229","article-title":"Lethal 17D yellow fever encephalitis in mice. I. Passive protection by monoclonal antibodies to the envelope proteins of 17D yellow fever and dengue 2 viruses","volume":"67","author":"Brandriss","year":"1986","journal-title":"J.\u00a0Gen. Virol."},{"key":"10.1016\/j.xcrm.2024.101655_bib70","doi-asserted-by":"crossref","first-page":"6008","DOI":"10.1016\/j.vaccine.2011.06.034","article-title":"Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model","volume":"29","author":"Julander","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.xcrm.2024.101655_bib71","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1056\/NEJMoa2000226","article-title":"Phase 1 Trial of a Therapeutic Anti-Yellow Fever Virus Human Antibody","volume":"383","author":"Low","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2024.101655_bib72","doi-asserted-by":"crossref","first-page":"956","DOI":"10.3389\/fimmu.2019.00956","article-title":"Role of Multivalency and Antigenic Threshold in Generating Protective Antibody Responses","volume":"10","author":"Slifka","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2024.101655_bib73","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.jaci.2013.10.037","article-title":"Transcutaneous yellow fever vaccination of subjects with or without atopic dermatitis","volume":"133","author":"Slifka","year":"2014","journal-title":"J.\u00a0Allergy Clin. Immunol."},{"key":"10.1016\/j.xcrm.2024.101655_bib74","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1046\/j.1365-3156.1999.00496.x","article-title":"Assessment of IgG antibodies against yellow fever virus after vaccination with 17D by different assays: neutralization test, haemagglutination inhibition test, immunofluorescence assay and ELISA","volume":"4","author":"Niedrig","year":"1999","journal-title":"Trop. Med. Int. Health"},{"key":"10.1016\/j.xcrm.2024.101655_bib75","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.4269\/ajtmh.1999.60.1045","article-title":"Comparison of the immunogenicity and safety of two 17D yellow fever vaccines","volume":"60","author":"Lang","year":"1999","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.xcrm.2024.101655_bib76","doi-asserted-by":"crossref","first-page":"4112","DOI":"10.1016\/j.vaccine.2018.05.041","article-title":"Duration of post-vaccination immunity to yellow fever in volunteers eight years after a dose-response study","volume":"36","author":"de Menezes Martins","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.xcrm.2024.101655_bib77","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1093\/infdis\/jiz374","article-title":"Persistence of Neutralizing Antibody Responses Among Yellow Fever Virus 17D Vaccinees Living in a Nonendemic Setting","volume":"221","author":"Kareko","year":"2020","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.xcrm.2024.101655_bib78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jtm\/tay108","article-title":"Persistence of yellow fever virus-specific neutralizing antibodies after vaccination among US travellers","volume":"25","author":"Lindsey","year":"2018","journal-title":"J. Travel Med."},{"key":"10.1016\/j.xcrm.2024.101655_bib80","article-title":"Flavivirus NS1 and Its Potential in Vaccine Development","volume":"9","author":"Carpio","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.xcrm.2024.101655_bib81","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1128\/jvi.60.3.1153-1155.1986","article-title":"Protection against yellow fever in monkeys by immunization with yellow fever virus nonstructural protein NS1","volume":"60","author":"Schlesinger","year":"1986","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.xcrm.2024.101655_bib82","doi-asserted-by":"crossref","first-page":"13735","DOI":"10.1128\/JVI.02178-12","article-title":"Characterization of CD8+ T\u00a0cell function and immunodominance generated with an H2O2-inactivated\u00a0whole-virus vaccine","volume":"86","author":"Walker","year":"2012","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.xcrm.2024.101655_bib83","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/nm.2763","article-title":"Development of a new hydrogen peroxide-based vaccine platform","volume":"18","author":"Amanna","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2024.101655_bib84","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1128\/JVI.02903-12","article-title":"A Hydrogen Peroxide-Inactivated Virus Vaccine Elicits Humoral and Cellular Immunity and Protects against Lethal West Nile Virus Infection in Aged Mice","volume":"87","author":"Pinto","year":"2013","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.xcrm.2024.101655_bib85","doi-asserted-by":"crossref","first-page":"7919","DOI":"10.4049\/jimmunol.0803903","article-title":"The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T\u00a0cell response","volume":"183","author":"Akondy","year":"2009","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.xcrm.2024.101655_bib86","doi-asserted-by":"crossref","first-page":"12794","DOI":"10.1128\/JVI.01160-13","article-title":"Yellow fever vaccination elicits broad functional CD4+ T\u00a0cell responses that recognize structural and nonstructural proteins","volume":"87","author":"James","year":"2013","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.xcrm.2024.101655_bib87","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S0264-410X(01)00457-1","article-title":"Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections","volume":"20","author":"Monath","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.xcrm.2024.101655_bib88","doi-asserted-by":"crossref","first-page":"60","DOI":"10.4161\/hv.2.2.2555","article-title":"Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes","volume":"2","author":"Guirakhoo","year":"2006","journal-title":"Hum. Vaccin."},{"key":"10.1016\/j.xcrm.2024.101655_bib89","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/nm1261","article-title":"Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus","volume":"11","author":"Edghill-Smith","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2024.101655_bib90","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.vaccine.2016.11.080","article-title":"Pre-clinical development of a hydrogen peroxide-inactivated West Nile virus vaccine","volume":"35","author":"Poore","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.xcrm.2024.101655_bib91","author":"Kohn"},{"key":"10.1016\/j.xcrm.2024.101655_bib92","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S0140-6736(63)90230-7","article-title":"Prophylactic Treatment of Small Pox Contacts with N-Methylisatin Beta-Thiosemicarbazone (Compound 33t57, Marboran)","volume":"2","author":"Bauer","year":"1963","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2024.101655_bib93","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1749-6632.1965.tb12545.x","article-title":"Clinical experience with the antiviral drug marboran (1-methylisatin 3-thiosemicarbazone)","volume":"130","author":"Bauer","year":"1965","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.xcrm.2024.101655_bib94","series-title":"The Specific Treatment of Virus Diseases","first-page":"86","author":"Bauer","year":"1977"},{"key":"10.1016\/j.xcrm.2024.101655_bib95","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0140-6736(66)92529-3","article-title":"Measuring methisazone serum-levels","volume":"288","author":"Gomez","year":"1966","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2024.101655_bib96","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1136\/bmj.1.5288.1317","article-title":"Eczema vaccinatum treated with n-methylisatin beta-thiosemicarbazone","volume":"1","author":"Turner","year":"1962","journal-title":"Br. Med. J."},{"key":"10.1016\/j.xcrm.2024.101655_bib97","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0140-6736(65)93003-5","article-title":"Measurement of N-methylisatin \u03b2-thiosemicarbazone serum levels","volume":"285","author":"Kempe","year":"1965","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2024.101655_bib98","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1128\/am.18.5.736-743.1969","article-title":"Yellow fever virus. II. Factors affecting the plaque neutralization test","volume":"18","author":"Spector","year":"1969","journal-title":"Appl. Microbiol."},{"key":"10.1016\/j.xcrm.2024.101655_bib99","first-page":"243","article-title":"International collaborative assay of the international reference preparation of anti-yellow-fever serum","volume":"33","author":"Krag","year":"1965","journal-title":"Bull. World Health Organ."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379124003690?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379124003690?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T17:59:38Z","timestamp":1728410378000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379124003690"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":98,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S2666379124003690"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2024.101655","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of a hydrogen peroxide-inactivated vaccine that protects against viscerotropic yellow fever in a non-human primate model","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2024.101655","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101655"}}